Skip to main content

Table 1 baseline characteristics and incidence of the outcome: Tehran Lipid and glucose study

From: External validation of the European risk assessment tool for chronic cardio-metabolic disorders in a Middle Eastern population

  Men (N = 1310) Women (N = 1960) p
Age (years)    < 0.001
 < 45 672 (51.3) 1065 (54.34)  
 ≤ 45 to > 50 165 (12.6) 258 (13.16)  
 ≤ 50 to > 55 121 (9.24) 215 (10.97)  
 ≤ 55 to > 60 108 (8.24) 177 (9.03)  
 ≤ 60 to > 65 73 (5.57) 129 (6.58)  
 ≤ 65 to > 70 89 (6.79) 70 (3.57)  
 ≤ 70 to > 75 60 (4.58) 35 (1.79)  
 ≤ 75 to > 85 22 (1.68) 11 (0.56)  
Total, mean (SD) 47.1 (12.8) 45.3 (11.3) < 0.001
Body mass index (kg/m2)    < 0.001
 < 25 440 (33.59) 394 (20.1)  
 ≤ 25 to < 30 615 (46.95) 845 (43.11)  
 ≥ 30 255 (19.47) 721 (36.79)  
 Total, mean (SD) 26.8 (4.0) 28.9 (4.6) < 0.001
Waist circumference (cm)    < 0.001
 Men < 94 and women < 80 576 (43.97) 307 (15.66)  
 Men ≥ 94 to < 102 and women ≥ 80 to < 88 410 (31.3) 436 (22.24)  
 Men ≥ 102 and women ≥ 88 324 (24.73) 1217 (62.09)  
 Total, mean (SD) 94.9 (10.4) 91.5 (11.6) < 0.001
Use of antihypertensive medications (yes) 42 (3.21) 148 (7.55) < 0.001
Current smoking (yes) 406 (30.99) 110 (5.61) < 0.001
Family history diabetes (yes) 440 (33.6) 624 (31.8) 0.29
Family history premature CVD (yes) 231 (17.63) 392 (20.0) 0.01
Incidence of chronic cardio-metabolic disorders 387 (29.54) 929 (47.4) < 0.001
T2DM
 De novo detected T2DM at baseline 64 (4.94) 90 (4.66) 0.71
 Incidence of T2DM 105 (8.01) 149 (7.6) 0.62
CKD
 De novo detected CKD at baseline 53 (4.0) 239 (12.2) < 0.0001
 Incidence of CKD 175 (13.3) 547 (27.9) < 0.0001
Incidence of CVD 73 (5.57) 49 (2.5) < 0.001
Follow-up duration, median (IQR) 6.26 (5.65–7.0) 6.22 (5.56–7.0) < 0.001
  1. Data are shown as mean (SD) for continues and number (%) for categorical covariates; IQR: Interquartile range; CVD: cardiovascular disease; T2DM: Type 2 diabetes; CKD; chronic kidney disease; CVD: cardiovascular disease